BioCentury
ARTICLE | Financial News

NASH company Terns raises $80M series B

November 2, 2018 8:03 PM UTC

Terns Pharmaceuticals Inc. (San Mateo, Calif.) will use its untranched $80 million series B funds to advance its acquired clinical and internally discovered preclinical non-alcoholic steatohepatitis assets.

The financing was led by new investors Vivo Capital and OrbiMed. New investor Decheng Capital also participated alongside existing investor Lilly Asia Ventures. The company launched in April 2017 with $30 million in series A funding from Lilly Asia Ventures...